OnKure Therapeutics (OKUR) Expected to Post Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) will likely be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.4067) per share and revenue of $0.17 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.23. On average, analysts expect OnKure Therapeutics to post ($1.47) EPS for the current fiscal year and ($1.15) EPS for the next fiscal year.

OnKure Therapeutics Stock Performance

Shares of OKUR traded down $0.04 during midday trading on Tuesday, hitting $2.55. 14,132 shares of the stock were exchanged, compared to its average volume of 265,732. OnKure Therapeutics has a 52-week low of $2.01 and a 52-week high of $5.38. The stock has a fifty day simple moving average of $2.88 and a 200 day simple moving average of $3.59. The firm has a market cap of $103.01 million, a P/E ratio of -0.73 and a beta of 0.12.

Analyst Ratings Changes

OKUR has been the topic of several research reports. HC Wainwright reduced their price target on shares of OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research report on Monday, July 20th. Weiss Ratings raised shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Finally, Oppenheimer reiterated an “outperform” rating and set a $14.00 target price on shares of OnKure Therapeutics in a report on Friday, August 14th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.50.

About OnKure Therapeutics

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.